Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PEYMAN GHASRI

NPI
1265498034
CMS profile
284787
Location
ENCINO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,643.67

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,558.67 190
Education $85.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PEYMAN GHASRI

NPI 1265498034 · CMS profile ID 284787

ENCINO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265498034?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PEYMAN GHASRI, NPI 1265498034, CMS profile ID 284787. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265498034?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PEYMAN GHASRI, NPI 1265498034, CMS profile ID 284787. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265498034?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PEYMAN GHASRI, NPI 1265498034, CMS profile ID 284787, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1265498034?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $3,643.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–191 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $27.8403/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174597877 CMS
Incyte Corporation $12.6703/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226071887 CMS
ABBVIE INC. $7.6103/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919550 CMS
MAYNE PHARMA COMMERCIAL LLC $0.6903/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254292871 CMS
MAYNE PHARMA COMMERCIAL LLC $6.6103/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254292881 CMS
Regeneron Healthcare Solutions, Inc. $33.1003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212927315 CMS
Arcutis Biotherapeutics, Inc. $7.7502/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252366345 CMS
Arcutis Biotherapeutics, Inc. $9.3002/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252366347 CMS
ABBVIE INC. $23.9402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919548 CMS
ABBVIE INC. $13.4202/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919546 CMS
GENZYME CORPORATION $44.4302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233395374 CMS
Novartis Pharmaceuticals Corporation $24.3402/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200333723 CMS
Galderma Laboratories, L.P. $12.8202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234644871 CMS
Botanix SB Inc $21.6702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246259229 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.4102/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251046080 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $4.1702/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251046082 CMS
Galderma Laboratories, L.P. $12.1102/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234644869 CMS
ABBVIE INC. $5.5002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919544 CMS
GENZYME CORPORATION $44.0502/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233395372 CMS
Surgenex LLC $31.3102/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254167717 CMS
Amgen Inc. $25.9002/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228320461 CMS
Galderma Laboratories, L.P. $12.0302/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234644867 CMS
Incyte Corporation $17.1202/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226070540 CMS
Regeneron Healthcare Solutions, Inc. $22.8802/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212927313 CMS
UCB, Inc. $47.9202/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224603893 CMS
Surgenex LLC $31.8102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254167331 CMS
Organon LLC $13.5501/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237682210 CMS
ABBVIE INC. $12.7501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919542 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $20.0701/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220086294 CMS
Galderma Laboratories, L.P. $16.4301/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234644865 CMS
ABBVIE INC. $17.0401/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919540 CMS
Arcutis Biotherapeutics, Inc. $18.6001/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252366343 CMS
GENZYME CORPORATION $37.0301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233395354 CMS
Regeneron Healthcare Solutions, Inc. $13.5501/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212927311 CMS
LEO Pharma Inc. $19.9901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252006732 CMS
Almirall LLC $13.6101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243883915 CMS
Surgenex LLC $22.7501/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254166751 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.3001/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251046088 CMS
ABBVIE INC. $12.4201/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201919538 CMS
MAYNE PHARMA COMMERCIAL LLC $18.8701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254292698 CMS
Journey Medical Corporation $23.0901/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250931885 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,311.44 71
PY2020 $1,437.33 72
PY2021 $2,405.42 89
PY2022 $1,892.42 102
PY2023 $2,578.55 146
PY2024 $2,691.02 135
PY2025 $3,643.67 191

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $16,815.68 51
PY2024 Principal investigator $36,077.30 15
PY2021 Principal investigator $10,200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,860.36 08/13/2025 Non-covered Recipient Entity
Amicis Research Center
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430670
Principal investigator 1 Incyte Corporation $2,257.00 06/04/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502300
Principal investigator 1 Incyte Corporation $1,805.60 05/02/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502296
Principal investigator 1 Incyte Corporation $2,031.30 05/02/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502304
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502101
Principal investigator 1 Incyte Corporation $49.50 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502105
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502108
Principal investigator 1 Incyte Corporation $242.70 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502116
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502121
Principal investigator 1 Incyte Corporation $600.30 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502125
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502129
Principal investigator 1 Incyte Corporation $440.85 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502133
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502137
Principal investigator 1 Incyte Corporation $17.15 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502141
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502146
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502151
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502155
Principal investigator 1 Incyte Corporation $161.80 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502158
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502161
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502166
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502170
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502173
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502178
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502182
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502186
Principal investigator 1 Incyte Corporation $1.72 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502190
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502194
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502199
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502203
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502207
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502211
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502216
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502220
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502224
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502228
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502233
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502237
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502242
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502246
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502251
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502255
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502259
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502265
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502269
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502273
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502276
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502281
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502284
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502288
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502292
Principal investigator 1 Incyte Corporation $1,766.70 01/08/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER VALENCIA
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240502112